Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Provided By PR Newswire
Last update: Jun 15, 2025
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA
Read more at prnewswire.com152.41
+0.4 (+0.26%)
Find more stocks in the Stock Screener
JNJ Latest News and Analysis
11 days ago - ChartmillJohnson & Johnson (NYSE:JNJ) - A Reliable Dividend Stock Worth ConsideringJohnson & Johnson (NYSE:JNJ) is a top dividend stock with a 3.32% yield, strong profitability, and a reliable payout history, making it a solid choice for income investors.
